Atara Biotherapeutics

CA - Thousand OaksBiotechnology1 H-1B visas (FY2023)

Focus: Atara Biotherapeutics is a cell therapy and immunotherapy specialist focused on gene therapy and cellular medicine for serious viral infections, autoimmune diseases, and oncology. The company operates as a mid-stage biotech with a diversified pipeline anchored in T-cell and CAR-T platforms.

Gene Therapy Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Atara Biotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Atara Biotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

10 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Cytomegalovirus-specific Cytotoxic T Lymphocytes

CMV Viremia

N/A

Clinical Trials (1)

NCT03010332Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease

N/A

Help build intelligence for Atara Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge cell therapy platforms (T-cell engineering, CAR-T, peptibodies) with expanding clinical validation across 10 active trials
Opportunity to work on first-in-class and differentiated immunotherapies in high-unmet-need indications including viral infections (CMV, EBV) and rare autoimmune disease (SLE, PPMS)
Location in Thousand Oaks, CA provides proximity to West Coast biotech ecosystem and talent market

Watch Out For

Zero approved products currently on market means limited revenue stream and ongoing cash burn dependency; no visibility to commercialization timeline
Early-stage pipeline with no Phase 3 programs—nearest catalyst is tabelecleucel in Phase 2 for EBV, requiring 2-4+ years to potential approval
Currently zero open job postings signals potential hiring freeze or organizational contraction; limited near-term career momentum and team growth

Generated by Claude from Atara Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ATA3219

Systemic Lupus Erythematosus

Phase 1

Clinical Trials (2)

NCT06256484A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Phase 1

NCT06429800A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

Phase 1

WT1-sensitized T cells

Leukemia

Phase 1

Clinical Trials (1)

NCT00620633Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation

Phase 1

CAR T cells

Malignant Pleural Mesothelioma

Phase 1

Clinical Trials (1)

NCT04577326Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Phase 1

Epstein-Barr virus-specific cytotoxic T lymphocytes

EBV-induced Lymphomas

Phase 1/2

Clinical Trials (1)

NCT00002663Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Phase 1/2

ATA188

Primary Progressive Multiple Sclerosis

Phase 1/2

Clinical Trials (1)

NCT03283826Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Phase 1/2

EBV-specific T cells

EBV-induced Lymphomas

Phase 2

Clinical Trials (1)

NCT01498484Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Phase 2

CMV-pp65-specific cytotoxic T lymphocytes

Cytomegalovirus Infection

Phase 2

CMV-pp65 CTLs

Cytomegalovirus

Phase 2

Clinical Trials (1)

NCT01646645Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

tabelecleucel

Epstein-Barr Virus Infections

Phase 2

Clinical Trials (1)

NCT02822495Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 10 clinical trials

Top TAs: Oncology, Immunology, Neurology

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

6 pipeline

Immunology

1 pipeline

Neurology

1 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (1)

2025-03-18

31 employees affected— CA

source

Source: state DOL filings, aggregated via Big Local News

No visible regulatory or workforce warnings on record, but absence of public hiring data and revenue raise execution risk questions.